Skip to content
Aminoscope
Head-to-head

Semaglutide vs Tesofensine

An approved drug with pivotal trials and a cardiovascular outcomes result against a single flagged Phase 2 number that was never confirmed. The evidence gap is the comparison.

By Julian RothResearch & dataUpdated October 2026

Short answer

Semaglutide has FDA approval and tesofensine does not, which is the main thing separating them. Semaglutide suits a reader who puts weight on FDA approval, while tesofensine is marketed for weight loss. On the evidence, semaglutide has approval-level evidence and tesofensine has human clinical data.

Semaglutide

Wegovy / Ozempic

FDA-approved

~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.

Full Semaglutide evidence review

Tesofensine

Clinical data

A triple monoamine reuptake inhibitor with ~9% Phase 2 weight loss — but flagged by a Lancet Expression of Concern, and its one completed Phase 3 (in Mexico) was never published or turned into an approval.

Full Tesofensine evidence review

Semaglutide vs Tesofensine: head to head

FDA status / approved use

Semaglutide

FDA-approved

Tesofensine

Investigational; not approved by the FDA or anywhere, despite a completed but unpublished phase III in Mexico
Marketed for

Semaglutide

Weight loss, type-2 diabetes

Tesofensine

Weight loss (marketed alongside GLP-1s)
Outcome areas

Semaglutide

Weight loss / appetite; Blood sugar / insulin sensitivity

Tesofensine

Weight loss / appetite
Evidence grade

Semaglutide

FDA-approved

Tesofensine

Clinical data
How it works

Semaglutide

GLP-1 receptor agonist

Tesofensine

Blocks reuptake of noradrenaline, dopamine and serotonin, raising all three
Route and dosing

Semaglutide

Subcutaneous, once weekly (Wegovy label); maintenance 2.4 mg (recommended) or 1.7 mg once weekly

Tesofensine

Not established
Headline human result

Semaglutide

14.9% mean weight loss vs 2.4% on placebo at 68 weeks (STEP 1, 2.4 mg weekly)

Tesofensine

About 9.2% weight loss at 0.5 mg over 24 weeks in the phase II TIPO-1 trial, later given an Expression of Concern
Strongest evidence

Semaglutide

STEP 1, NEJM 2021Semaglutide evidence reviewPubMed 33567185

Tesofensine

Astrup, Lancet 2008Tesofensine evidence reviewPubMed 18950853
Key safety signal

Semaglutide

Nausea, vomiting and constipation, mainly when the dose is raised too quickly

Tesofensine

Raised heart rate by 7.4 beats per minute; dry mouth, nausea, constipation and insomnia
How it is obtained

Semaglutide

Prescription. Manufacturer self-pay for Wegovy (injection pen) runs $349–$399 per fill, against a $1,349 list priceWegovy cost breakdown

Tesofensine

Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

This one is not close. Semaglutide is approved, cut mean body weight by about 14.9% in STEP 1, and reduced major adverse cardiovascular events by roughly 20% in SELECT. Tesofensine is an investigational triple monoamine reuptake inhibitor; its headline 9.2% at the 0.5 mg dose comes from one 24-week Phase 2 trial that later received a Lancet Expression of Concern, a Phase 3 run in Mexico was announced by press release but never published in a peer-reviewed journal, and it is not approved in the US. It also raised heart rate by 7.4 beats per minute at that dose, a stimulant-class signal rather than an incretin one. The two have never been compared directly, and given the state of the tesofensine record they are not really comparable.

Semaglutide fits if

You want a weight-loss drug with pivotal trials, an approval, and hard cardiovascular outcome data.

Tesofensine fits if

There is no treatment case here; tesofensine is worth reading only if you follow unsettled obesity pharmacology and want to understand why a striking Phase 2 result never became a drug.

Semaglutide vs Tesofensine: common questions

Is semaglutide FDA-approved but tesofensine not?
Yes. Semaglutide is FDA-approved. Tesofensine is investigational; not approved by the FDA or anywhere, despite a completed but unpublished phase III in Mexico.
Which has stronger human evidence, semaglutide or tesofensine?
Semaglutide. It has approval-level evidence (key source: STEP 1, NEJM 2021), while tesofensine has human clinical data (key source: Astrup, Lancet 2008).
What are the main safety concerns with semaglutide and tesofensine?
For semaglutide, watch for nausea, vomiting and constipation, mainly when the dose is raised too quickly. Tesofensine raised heart rate by 7.4 beats per minute; dry mouth, nausea, constipation and insomnia.

Key studies behind each

Semaglutide

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
  2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. PubMed 33755728
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PubMed 37952131
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024

Tesofensine

  1. Astrup A, Madsbad S, Breum L, et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. PubMed 18950853
  2. The Lancet. (2013). Expression of concern—Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. PubMed 23561987
  3. Lehr T, Staab A, Tillmann C, et al. (2008). Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol. PubMed 17982477
  4. Huynh K, Klose M, Krogsgaard K, et al. (2022). Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. PubMed 35294397

The full evidence reviews

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Tesofensine availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: Always Wellness and RecoveryAmbiante Health & WellnessArc-1Ark HealthARSYNL RxAscend Vitality

Related comparisons